动物实验,急性骨髓性白血病 z-bo 2020-10-21 364

　　New research shows that nanoparticles carrying miR-22, a small non-coding RNA molecule that can regulate gene expression, may have a therapeutic effect on mouse models of acute myeloid leukemia.

　　Acute myeloid leukemia is a type of blood cell cancer that often kills patients within 5 years of intensive chemotherapy. Currently, there is a lot of information about the characteristics of genomic mutations in acute myeloid leukemia, but little is known about the molecular mechanisms that promote the transformation of precursor cells into cancer cells. Chen Jianjun's research team at the University of Cincinnati in the United States analyzed the cancer samples of 62 patients and found that the expression of miR-22 was reduced in patients with acute myeloid leukemia. Studies using various mouse models of acute myeloid leukemia have shown that miR-22 expression can be restored by blocking certain cell conduction pathways and preventing the development of acute myeloid leukemia and the maintenance of cancer cells.

　　Next, the researchers used nanoparticles to deliver short-chain miR-22NA to two leukemia mouse models and evaluated the effectiveness of miR-22 treatment. In both models, treatment with miR-22 slowed the progression of cancer and prolonged survival. However, the researchers pointed out that further tests are needed before miR-22-carrying nanoparticles can be used in clinical trials for the treatment of acute myeloid leukemia. They also said that combining this therapy with standard chemotherapy drugs can effectively treat acute myeloid leukemia.